Get started
Author

Daniël Martijn Jonker

Observed names: D JONKER, D Jonker, D M Jonker, D. M. Jonker, D.M. Jonker, Daniel Jonker, Daniel M. Jonker, Daniël Jonker, Daniël M. Jonker, Daniël M. Jonker, Jonker, Daniel Martijn
Observed institutions: Leiden University, Texas Tech University, Uppsala University, University of Helsinki, Novo Nordisk (Denmark), Ferring Pharmaceuticals (Denmark), Stichting Epilepsie Instellingen Nederland
ORCID: 0000-0002-8227-9361
Observed ORCID: 0000-0002-8227-9361
OpenAlex ID: A5008224959
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
2007 · Radojka M. Savic, Daniël M. Jonker, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 514
Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers
2002 · P. D. Knoester, D. M. Jonker, et al. · British Journal of Clinical Pharmacology · 157
Towards a mechanism-based analysis of pharmacodynamic drug?drug interactions in vivo
2004 · D JONKER, S VISSER, et al. · Pharmacology & Therapeutics · 134
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data
2005 · D JONKER, L KENNA, et al. · Clinical Pharmacology & Therapeutics · 84
Synergistic Combinations of Anticonvulsant Agents: What Is the Evidence from Animal Experiments?
2007 · Daniël M. Jonker, Rob A. Voskuyl, et al. · Epilepsia · 58
PDF
Population Pharmacokinetics of Liraglutide, a Once‐Daily Human Glucagon‐Like Peptide‐1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice‐Daily Exenatide
2010 · Estelle Watson, Daniël M. Jonker, et al. · The Journal of Clinical Pharmacology · 54
Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment
2011 · Steen H. Ingwersen, Manoj Khurana, et al. · The Journal of Clinical Pharmacology · 35
Pharmacodynamic Analysis of the Anticonvulsant Effects of Tiagabine and Lamotrigine in Combination in the Rat
2004 · Daniël M. Jonker, Rob A. Voskuyl, et al. · Epilepsia · 22
Characterization of the decrease of extracellular striatal dopamine induced by intrastriatal morphine administration
1999 · T Petteri Piepponen, Janne A V Mikkola, et al. · British Journal of Pharmacology · 16
PDF
Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations
2019 · Yassine Kamal Lyauk, Daniël Martijn Jonker, et al. · Clinical and Translational Science · 13
PDF
Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization
2007 · M. Danhof, P.H. Van der Graaf, et al. · Elsevier eBooks · 13
Pharmacodynamic Analysis of the Interaction between Tiagabine and Midazolam with an Allosteric Model That Incorporates Signal Transduction
2003 · Daniël M. Jonker, Dick A. C. Vermeij, et al. · Epilepsia · 12
Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
2020 · Yassine Kamal Lyauk, Daniël M. Jonker, et al. · The AAPS Journal · 10
PDF
Anticonvulsant drugs differentially suppress individual ictal signs: A pharmacokinetic/pharmacodynamic analysis in the cortical stimulation model in the rat.
2003 · D. M. Jonker, C. van de Mheen, et al. · Behavioral Neuroscience · 10
Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women
2022 · Feng Shao, Yi Jiang, et al. · Clinical Drug Investigation · 9
PDF
Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
2020 · Yassine Kamal Lyauk, Trine Meldgaard Lund, et al. · The AAPS Journal · 5
PDF
First pre-filled pen device with highly purified human menopausal gonadotropin (HP-hMG, Menopur) in liquid is shown to be bioequivalent to powder for reconstitution
2021 · Daniël M. Jonker, Manuela Koch, et al. · International Journal of Clinical Pharmacology and Therapeutics · 4
PDF
Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
2021 · Yassine Kamal Lyauk, Daniël M. Jonker, et al. · The AAPS Journal · 4
PDF
First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support
2025 · Yu Bagger, Carina Holmqvist, et al. · Clinical Pharmacology in Drug Development · 3
PDF
P–650 Body weight is the main determinant of systemic follicle stimulating hormone (FSH) concentrations during controlled ovarian stimulation with follitropin delta
2021 · D Jonker · Human Reproduction · 3
P-671 Modelling human follicle growth and development during ovarian stimulation: a physiological computational approach
2024 · M Behar, A Sode, et al. · Human Reproduction · 1
PDF
No Measurable Transfer of Oxytocin-Receptor Agonist Merotocin Detected in Human Breast Milk
2024 · Teresa Baker, Ulrike Lorch, et al. · Breastfeeding Medicine · 1
PDF
Impact of body weight on ovarian response after individualized or fixed follicle-stimulating hormone dosing in women undergoing ovarian stimulation for in vitro fertilization
2019 · Scott M. Nelson, Antonio La Marca, et al. · Fertility and Sterility · 1
The Effect of Carbetocin on Cardiac Repolarization: A Randomized, Placebo‐ and Positive‐Controlled QT / QTc Study in Healthy Adults
2026 · Daniël M. Jonker, Katie Barletta, et al. · Clinical and Translational Science
PDF
O-013 Population pharmacokinetics of follitropin delta during ovarian stimulation
2024 · P Heiser, P Pinton, et al. · Human Reproduction
Works count: 32
Citation count: 1,163
H-index: 12
I10-index: 14
Year
Topic
Type